Genmab and Seagen submit cancer drug application to US FDA
The US FDA will evaluate a cervical cancer treatment developed by Genmab and Seagen
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
Danish biotech firm Genmab and US biotech firm Seagen have applied for an accelerated approval of the drug candidate tisotumab vedotin at the US Food and Drug Administration, according to a Genmab press release on Wednesday.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.